Transcriptomic profiling of oxaliplatin-resistant colorectal cancer (CRC) cells derived from DLD1 and HCT116 identified ALCAM activation with concurrent CD22, CASP1, and CISH suppression as key molecular features of oxaliplatin non-response [22]. This evidence concerns the gene CD22 and colorectal carcinoma.